STEINMAN LAWRENCE - 30 Sep 2021 Form 4 Insider Report for 180 Life Sciences Corp. (ATNF)

Role
Director
Signature
/s/ Lawrence Steinman, M.D.
Issuer symbol
ATNF
Transactions as of
30 Sep 2021
Transactions value $
$31,296
Form type
4
Filing time
05 Oct 2021, 08:16:21 UTC
Previous filing
17 Sep 2021
Next filing
03 Nov 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATNF Common Stock Award $31,296 +5,216 +0.88% $6* 597,574 30 Sep 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On September 30, 2021, the Issuer entered into a Debt Conversion Agreement with the Reporting Person, pursuant to which the parties agreed to convert an aggregate of $31,297 owed by the Registrant to the Reporting Person, for advances previously made to the Registrant's subsidiaries, into an aggregate of 5,216 shares of common stock of the Issuer. Exempt from Section 16(b) pursuant to Rule 16b-3.
F2 The agreed upon conversion price of the conversion of the debt described in Footnote (1) above was the greater of the closing consolidated bid price or the market price on the date the conversion agreement was entered into, and $6.00 per share, provided that because $6.00 was above the closing consolidated bid price and the market price, the conversion price was fixed at $6.00 per share.